- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: World Mental Health Day.
Displaying page 1 of 1.
EudraCT Number: 2020-000102-28 | Sponsor Protocol Number: AFJ2020-1 | Start Date*: 2020-08-19 | |||||||||||
Sponsor Name:Mental Healt Center Copenhagen | |||||||||||||
Full Title: Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration in glycaemic control in prediabetic or diabetic patients with schizophrenia spectrum disorder treated with the an... | |||||||||||||
Medical condition: Schizophrenia spectrum disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003343-11 | Sponsor Protocol Number: GLP1ALCOHOL | Start Date*: 2017-04-12 | |||||||||||
Sponsor Name:Psychiatric Centre Copenhagen | |||||||||||||
Full Title: Does Glucagon-like Peptide 1 (GLP-1) receptor stimulation reduce alcohol intake in patients with alcohol dependence? | |||||||||||||
Medical condition: Alcohol dependence | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004088-31 | Sponsor Protocol Number: B4Z-XM-LYDM | Start Date*: 2005-04-19 | |||||||||||
Sponsor Name:Lilly S.A. | |||||||||||||
Full Title: A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 weeks in Newly Diagnosed Children and Adolescents Outpatients with Attention-Deficit/Hyp... | |||||||||||||
Medical condition: Attention-Deficit/Hyperactivity Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015844-41 | Sponsor Protocol Number: BMN162-502 | Start Date*: 2013-07-25 | |||||||||||
Sponsor Name:BioMarin International Ltd. | |||||||||||||
Full Title: A Phase IV Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4 to 5 Year-Old Children with Phenylketonuria Treated with Sapropterin Dihydrochloride (Kuvan®) for 7 Years. | |||||||||||||
Medical condition: Phenylketonuria | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000859-14 | Sponsor Protocol Number: CC-10004-PSOR-010 | Start Date*: 2013-01-17 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, In Subjects with Moderate to... | |||||||||||||
Medical condition: Psoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world's population. Plaque-type psoriasis is the most common form of this disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (Completed) NL (Completed) CZ (Completed) LV (Completed) EE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000054-28 | Sponsor Protocol Number: OLIGOTREAT | Start Date*: 2023-06-02 | |||||||||||
Sponsor Name:Klinikum der Universität München | |||||||||||||
Full Title: Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat) | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001153-17 | Sponsor Protocol Number: 262 | Start Date*: 2008-06-16 | |||||||||||
Sponsor Name:MSD | |||||||||||||
Full Title: Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combinat... | |||||||||||||
Medical condition: Postmenopausal women with osteoporosis at increased risk of falls. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) ES (Completed) LT (Completed) GB (Completed) BE (Completed) LV (Completed) FR (Completed) IE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000140-58 | Sponsor Protocol Number: NL7255100000 | Start Date*: 2020-07-23 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Complement Inhibition: Attacking the Overshooting Inflammation @fter Traumatic Brain Injury - A phase II trial on the safety and efficacy of C1 esterase inhibitor Cinryze for the acute management o... | |||||||||||||
Medical condition: Severe traumatic Brain Injury (TBI) with GCS < 13 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000471-14 | Sponsor Protocol Number: TRA105325 | Start Date*: 2006-06-13 |
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
Full Title: EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopa... | ||
Medical condition: Immune thrombocytopenic purpura (ITP) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SI (Completed) SE (Completed) DE (Completed) ES (Completed) IE (Completed) NL (Completed) GR (Completed) FR (Completed) SK (Completed) GB (Completed) CZ (Completed) DK (Completed) IT (Completed) FI (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-002369-14 | Sponsor Protocol Number: CHUB-Psy-PAThforsAUD | Start Date*: 2023-07-20 | |||||||||||
Sponsor Name:CHU Brugmann | |||||||||||||
Full Title: Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)cognitive Mechanisms. | |||||||||||||
Medical condition: Severe Alcohol Use Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
